According to the company, the patents cover the use of prolactin alone, as well as in combination with other therapeutics that augment recovery and therefore provide a broad base of protection. These are the first patents to issue in Prolactin patent family.
This intellectual property supports programs currently under development using prolactin alone or with anti-inflammatories to treat multiple sclerosis and using a combination of prolactin and EPO to treat other neurodegenerative diseases.
Alan Moore, President and CEO of Stem Cell, said: “We have the exclusive right to the use of prolactin for treating neurodegenerative diseases and therefore have a strong foundation to develop many possible products using prolactin, either as a single therapeutic or in combination with other neurogenic agents.”